Social Media Ideas for Hcvax

Evaxion Presents New Preclinical Data for AI-Designed CMV Vaccine Program EVX-V1

New preclinical findings show AI-discovered T-cell epitopes may improve control of CMV infection.

Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial

Atea Pharmaceuticals’ hepatitis C prospect has matched Gilead’s Epclusa in a phase 3 trial, keeping the biotech barreling toward a second readout for its shorter, simpler treatment...

<![CDATA[Osivax And GC Biopharma Enter Collaboration to Develop Next Generation Influenza Vaccine ]]>

Atea outlines peak annual U.S. net revenue potential in excess of $700M with focus on mid-2028 HCV launch

More Pancreatic Cancer Vaccine Progress - Treatment and Preventative

More Pancreatic Cancer Vaccine Progress - Treatment and Preventative Anonymous (not verified) Mon, 07/20/2026 - 15:19 pharmagather item url More Pancreatic...

Labcorp launches new hepatitis D test to find patients with most severe form of virus

Labcorp is looking to plug the gap in hepatitis D monitoring with a new reflex testing solution to help find more patients with this form of the virus earlier.

The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble

Design of an immunogen containing multidimensionally conserved and immunogenic parts of the HIV proteome

by Eric Wang, Arup K. Chakraborty Despite decades of research, an effective HIV vaccine or cure has not yet been developed. An important reason is the virus’s mutability, which al...

INVIVYD

INVIVYD Anonymous (not verified) Tue, 08/04/2026 - 21:28 field_thread_url https://cafepharma.com/boards/threads/invivyd.703943/ board na...

Medigen links up with Charles River in push to take enterovirus vaccine global

Charles River Laboratories and Taiwan-based Medigen Vaccine Biologics are teaming up to advance Medigen’s multivalent enterovirus vaccine.

Vaccine may ‘intercept’ pancreatic cancer before it starts

An investigational vaccine that targets common KRAS mutations induced durable immune responses among individuals at high risk for pancreatic cancer, results of a phase 1 clinical t...

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Ta...

Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months

Precision BioSciences: Promising HBV Editing Evidence

Mavyret Patent Abandonment Does Not Open the Field for Hepatitis C Generics

July 28, 2026 marked eight years of the National Viral Hepatitis Control Program (NVHCP). Launched under the National Health Mission, the program aims to eliminate Hepatitis C from...

Join Virax's Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial Execution

CEO James Foster to discuss the Company's financial and strategic position, commercial strategy for ImmuneSelect and development plans for ViraxImmuneâ„¢Webinar to include an overv...

<![CDATA[GSK Advances mRNA Flu Vaccine to Phase III ]]>

New study finds hexavalent vaccine could make India's immunization program more efficient and family-friendly

A study appearing in Human Vaccines & Immunotherapeutics found that introducing the hexavalent (six-in-one) vaccine into India's Universal Immunization Program (UIP) could impr...

Hartford Conservative Allocation Fund Q2 2026 Commentary

Common Health Coalition secures $100M from OpenAI Foundation to boost hepatitis C cure rates

Funding will support the deployment of AI-enabled tools to help identify patients who have fallen out of care, reduce administrative burden, strengthen care coordination and improv...